Providing Communicative/Evidence-Based Integrative Kidney Cancer Care

Video

According to an expert from University Hospitals, integrative oncology has a place in the treatment of patients with kidney cancer alongside palliative care, psycho-oncology, and physical therapy.

CancerNetwork® spoke with Santosh Rao, MD, in an interview during Kidney Cancer Awareness Month 2023 about how integrative oncology fits into multidisciplinary care strategies along with surgical, radiation, and medical oncology for patients with kidney cancer.

Rao, medical director of integrative oncology for University Hospitals Connor Whole Health and president-elect for the Society for Integrative Oncology, also indicated that integrative oncology consults are important tools for guiding patients using strong communication and evidence-based methods.

Transcript:

We have to think creatively. When I think of multidisciplinary care, it’s obviously [disciplines such as] surgical, radiation, and medical oncology which includes chemotherapy and immunotherapy. And you look for the issues that can come up throughout that whole journey. I don’t think of it as just integrative oncology. Integrative oncology is a broad term that involves a lot of different things.

But it has a certain place which can be alongside palliative care, psycho-oncology, and physical therapy. All these different things that we employ such as social work affect all patients with cancer in some ways or another at different times. Kidney cancer is no different. If you [have] depression, for example, what are the resources that can really help someone? That’s really the way I think about it.

The other thing we didn’t talk about is that many people have a lot of questions. One of the things that I do is integrative oncology consults. We will look at someone’s lifestyle and how they manage their stress, and we’ll also talk about questions that they have and what supplements and natural products they’re using.

That, as we’ve seen, is a huge business. Many people have all sorts of important questions, but if you don’t have any guidance, people are just going online and reading stuff. And we know that they don’t always bring it up with their physician. Also, many people don’t understand what to tell patients [about] what [products are] safe, not safe, et cetera. That’s important too. Whether you’re treating kidney cancer or another cancer, it comes up. Getting good guidance, communicating and collaborating, and doing it in an evidence-based way is also important.

Recent Videos
“This is something where this is written by the trainees, for the trainees, and, of course, for all the other clinicians who take care of patients,” said Kiran Turaga, MD, MPH.
“Everyone—patients, doctors—we all want the same thing. We want [patients] to live longer,” said Kiran Turaga, MD, MPH, on patients with peritoneal surface malignancies.
Data from the phase 3 DeLLphi-304 trial at ASCO 2025 revealed a survival advantage with tarlatamab vs chemotherapy in second-line ES-SCLC.
The new peritoneal surface malignancy care guidelines had clinicians gather from every disease state to show increased representation.
The FDA approval of tarlatamab in SCLC has received much press attention, according to Daniel R. Carrizosa, MD, MS.
These new guidelines aim to alleviate some of the problems caused by patients with peritoneal metastases being diagnosed with the disease in late stages.
A combined cohort composed of patients from the TROPION-Lung01 and TROPION-Lung-05 trials showed a survival advantage with dato-DXd vs docetaxel.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
Osimertinib/chemotherapy and amivantamab/lazertinib have exhibited an efficacy advantage vs osimertinib in patients with EGFR-mutant NSCLC.
One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.
Related Content